Genetic metabolic polymorphisms and the risk of cancer: A review of the literature

被引:157
作者
dErrico, A
Taioli, E
Chen, X
Vineis, P
机构
[1] NYU, MED CTR, INST ENVIRONM MED, NEW YORK, NY 10010 USA
[2] OSPED MAGGIORE, EPIDEMIOL UNIT, MILAN, ITALY
[3] NYU, KAPLAN COMPREHENS CANC CTR, NEW YORK, NY USA
基金
美国国家卫生研究院;
关键词
cancer; metabolic polymorphisms; cancer susceptibility genes; GSTM1; NAT2; CYP2D6; CYP1A1; AHH;
D O I
10.3109/13547509609079352
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The purpose of this paper is to systematically analyse the design and results of epidemiological studies on the association between various types of cancer (lung, bladder, breast, colon, stomach) and four genetically-based metabolic polymorphisms, involved in the metabolism of several carcinogens (glutathione-S-transferase M1, debrisoquine hydroxylase, N-acetyltransferase, aryl hydrocarbon hydroxylase). These inherited polymorphisms usually cause modifications in the quality or quantity of the relevant enzymes. Such enzymes are involved in the activation/inactivation of known carcinogens and seem to modify the extent to which carcinogens interact with DNA in target tissues. Two enzymes, debrisoquine hydroxylase and aryl hydrocarbon hydroxylase, activate procarcinogens to carcinogens (phase I enzymes). The other two, glutathione-S-transferase M1 and N-acetyltransferase, mainly detoxify carcinogenic substances (phase II enzymes). Because of their role as host factors (modulating the action of carcinogens), it has been hypothesized that subjects presenting a specific phenotype for such polymorphisms could be at a greater risk of developing various types of cancer. A number of epidemiological studies have investigated such associations, often with discordant results. We examine and discuss the design of the studies, and present a meta-analysis of the available data.
引用
收藏
页码:149 / 173
页数:25
相关论文
共 125 条
  • [11] GENETIC-HETEROGENEITY OF THE HUMAN GLUTATHIONE TRANSFERASES - A COMPLEX OF GENE FAMILIES
    BOARD, P
    COGGAN, M
    JOHNSTON, P
    ROSS, V
    SUZUKI, T
    WEBB, G
    [J]. PHARMACOLOGY & THERAPEUTICS, 1990, 48 (03) : 357 - 369
  • [12] BROCKMOLLER J, 1993, CANCER RES, V53, P1004
  • [13] BROCKMOLLER J, 1994, CANCER RES, V54, P4103
  • [14] EXTENSIVE METABOLIZERS OF DEBRISOQUINE BECOME POOR METABOLIZERS DURING QUINIDINE TREATMENT
    BROSEN, K
    GRAM, LF
    HAGHFELT, T
    BERTILSSON, L
    [J]. PHARMACOLOGY & TOXICOLOGY, 1987, 60 (04): : 312 - 314
  • [15] RELATIONSHIP OF CYP2D6 (DEBRISOQUINE HYDROXYLASE) GENOTYPE TO BREAST-CANCER SUSCEPTIBILITY
    BUCHERT, ET
    WOOSLEY, RL
    SWAIN, SM
    OLIVER, SJ
    COUGHLIN, SS
    PICKLE, L
    TROCK, B
    RIEGEL, AT
    [J]. PHARMACOGENETICS, 1993, 3 (06): : 322 - 327
  • [16] ACETYLATOR PHENOTYPE IN PATIENTS WITH BREAST-CANCER
    BULOVSKAYA, LN
    KRUPKIN, RG
    BOCHINA, TA
    SHIPKOVA, AA
    PAVLOVA, MV
    [J]. ONCOLOGY, 1978, 35 (04) : 185 - 188
  • [17] BURGESS EJ, 1985, EUR J RESPIR DIS, V67, P17
  • [18] CAPORASO N, 1989, CANCER RES, V49, P3675
  • [19] LUNG-CANCER AND THE DEBRISOQUINE METABOLIC PHENOTYPE
    CAPORASO, NE
    TUCKER, MA
    HOOVER, RN
    HAYES, RB
    PICKLE, LW
    ISSAQ, HJ
    MUSCHIK, GM
    GREENGALLO, L
    BUIVYS, D
    AISNER, S
    RESAU, JH
    TRUMP, BF
    TOLLERUD, D
    WESTON, A
    HARRIS, CC
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (15) : 1264 - 1272
  • [20] GENETICALLY-DETERMINED DEBRISOQUINE OXIDATION CAPACITY IN BLADDER-CANCER
    CARTWRIGHT, RA
    PHILIP, PA
    ROGERS, HJ
    GLASHAN, RW
    [J]. CARCINOGENESIS, 1984, 5 (09) : 1191 - 1192